期刊文献+

柳氮磺吡啶 甲氨喋呤联合治疗强直性脊柱炎54例疗效观察 被引量:3

暂未订购
导出
摘要 目的 观察柳氮磺吡啶与甲氨喋呤联合应用对强直性脊柱炎的临床疗效。方法 强直性脊柱炎患者 5 4%口服柳氮磺吡啶 1周 ,0 5g、2次/d ,第 2周以后 ,1 g,2次 /d ;口服甲氨喋呤 ,第 1周 7 5mg,每周1次 ,第 2周以后 :1 0mg,每周 1次。对照组 :口服柳氮磺吡啶 ,第 1周 0 5 g,2次 /d,第 2周以后 ,2g,2次 /d,第 1月加用双氯芬酸钠 5 0mg ,3次/d。疗程均多 6个月。 结果 治疗组总有效率 96 3 0 %。对照组85 1 9% ,两者比较差异有显著性 (χ2 =3 97,P <0 0 5 )。
作者 赵建宏
出处 《济宁医学院学报》 2003年第1期38-39,共2页 Journal of Jining Medical University
  • 相关文献

参考文献3

二级参考文献5

共引文献108

同被引文献62

  • 1谢锐龙,李晓昊,康贤通.甲氨喋呤与美洛昔康联合治疗强直性脊柱炎的临床观察[J].第一军医大学学报,2003,23(5):460-462. 被引量:5
  • 2[1]Smolen JS,Kalden JR,Scott DI,et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised,multicentre trial[J]. Lancet, 1999, 353(9149): 259.
  • 3[2]Cherwinski HM, Byars N, Ballaron SJ, et al. Leflunomide interferes with pyramidine nucleotide biosynthesis [J].Inflamm Res, 1995, 44(8): 317.
  • 4[3]Herrmann M, Frangou CG, Kirschbaum B. Cell cycle control of the de novo pyrimidine synthesis inhibitor leflunomide through the p53 and p21WAF-1 pathways[J].ACR Poster Session,2000, Abstract: 875.
  • 5[4]Xu X, Williams JW, Gong H, et al. Two activities of the immunosuppressive metabolite of leflunomide, A77 1726.Inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation[J]. Biochem Pharmacol, 1996, 52(4): 527.
  • 6[5]Klausner RD, Samelson LE. T cell antigen receptor activation pathway: the tyrosine kinase connection[J]. Cell,1991, 64(5): 875.
  • 7[6]Mattar T, Kochhar K, Bartlett R, et al. Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide[J]. FEBS Lett, 1993, 334(2): 161.
  • 8[7]Shawver LK, Schwartz DP, Mann E, et al. Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N- [4- (trifluoromethyl) -phenyl] 5-methylisoxazole -4- carboxamide[J]. Clin Cancer Res, 1997,3(7): 1167.
  • 9[8]Xu X, Shen J, Mall JW , et al. In vitro and in vivo antitumor activity of a novel immunomodulatory drug, leflunomide:mechanisms of action[J]. Biochem Phamacol, 1999, 58(9):1405.
  • 10[9]Manna SK, Aggarwal BB. Immunosuppressive leflunomide metabolite (A77 1726 ) blocks TNF-dependent nuclear factor-κB activation and gene expression [J]. J Immunol, 1999, 162(4): 2095.

引证文献3

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部